Table 3.
VTE risk scoring systems for patients with cancer63
| Score name and year published | Khorana score33 (2008) |
Vienna CATS score57 (2010) |
PROTECHT score58 (2012) |
CONKO score59 (2013) |
| Parameter | ||||
| Very high-risk tumours (pancreatic, gastric) | 2 | 2 | 2 | 2 |
| High-risk tumours (lung, gynaecological, lymphoma, bladder, testicular) | 1 | 1 | 1 | 1 |
| Pre-chemotherapy haemoglobin <10 g/dL or use of an ESA | 1 | 1 | 1 | 1 |
| Pre-chemotherapy white blood cell count >11×109/L | 1 | 1 | 1 | 1 |
| Pre-chemotherapy platelet count ≥350×109/L | 1 | 1 | 1 | 1 |
| Body mass index ≥35 kg/m2 | 1 | 1 | 1 | – |
| D-dimer >1.44 µg/L | – | 1 | – | – |
| Soluble P-selectin >53.1 ng/L | – | 1 | – | – |
| Gemcitabine chemotherapy | – | – | 1 | – |
| Platinum-based chemotherapy | – | – | 1 | – |
| WHO performance status ≥2 | – | – | – | 1 |
Each number indicates the number of points assigned to each parameter if it is present; – indicates that the parameter is not part of the respective scoring system.
CATS, Cancer and Thrombosis Study; ESA, erythropoiesis-stimulating agent; VTE, venous thromboembolism.